HK1206997A1 - Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions - Google Patents

Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions

Info

Publication number
HK1206997A1
HK1206997A1 HK15107727.8A HK15107727A HK1206997A1 HK 1206997 A1 HK1206997 A1 HK 1206997A1 HK 15107727 A HK15107727 A HK 15107727A HK 1206997 A1 HK1206997 A1 HK 1206997A1
Authority
HK
Hong Kong
Prior art keywords
ischemia
stroke
specific binding
human antibodies
binding sequences
Prior art date
Application number
HK15107727.8A
Other languages
English (en)
Chinese (zh)
Inventor
Moses Rodriguez
Arthur E Warrington
Larry R Pease
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of HK1206997A1 publication Critical patent/HK1206997A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15107727.8A 2012-04-17 2015-08-11 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions HK1206997A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625628P 2012-04-17 2012-04-17
PCT/US2013/036947 WO2013158748A1 (fr) 2012-04-17 2013-04-17 Anticorps humains et séquences de liaison spécifiques de ceux-ci à utiliser pour un accident vasculaire cérébral et une ischémie ou des états ischémiques

Publications (1)

Publication Number Publication Date
HK1206997A1 true HK1206997A1 (en) 2016-01-22

Family

ID=49384031

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15107727.8A HK1206997A1 (en) 2012-04-17 2015-08-11 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
HK15108177.1A HK1207565A1 (en) 2012-04-17 2015-08-24 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
HK19100777.8A HK1258380A1 (zh) 2012-04-17 2019-01-17 用於中風和缺血或缺血性病況的人抗體及其特異性結合序列

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15108177.1A HK1207565A1 (en) 2012-04-17 2015-08-24 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
HK19100777.8A HK1258380A1 (zh) 2012-04-17 2019-01-17 用於中風和缺血或缺血性病況的人抗體及其特異性結合序列

Country Status (13)

Country Link
US (1) US20150104460A1 (fr)
EP (2) EP3305323B1 (fr)
JP (5) JP6162219B2 (fr)
CN (2) CN104379167B (fr)
BR (1) BR112014025898A2 (fr)
CA (1) CA2870625C (fr)
ES (2) ES2870717T3 (fr)
HK (3) HK1206997A1 (fr)
IL (2) IL235118B (fr)
IN (1) IN2014MN02274A (fr)
MX (1) MX356347B (fr)
NZ (1) NZ701278A (fr)
WO (1) WO2013158748A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
KR20230155600A (ko) 2014-04-03 2023-11-10 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
US11180543B2 (en) 2014-11-07 2021-11-23 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
ES2874558T3 (es) 2015-03-04 2021-11-05 Igm Biosciences Inc Moléculas de unión a CD20 y usos de las mismas
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法
CN113444787A (zh) * 2021-07-05 2021-09-28 中山大学附属第七医院(深圳) 一种自闭症的脂质生物标志物及其应用
CN114276418B (zh) * 2021-12-28 2024-06-25 中国科学技术大学 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2150262C (fr) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP2287191B1 (fr) 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Anticorps igm humains dotés de la capacité d'induire une remyélinisation, utilisations diagnostiques et thérapeutiques pour le système nerveux central
CA2525917C (fr) 2003-05-16 2017-07-04 Mayo Foundation For Medical Education & Research Compositions et procedes comprenant un anticorps monoclonal recombinant qui promeut la remyelinisation du systeme nerveux central
TW200510532A (en) * 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
PL1768999T3 (pl) * 2004-06-30 2013-12-31 Mayo Found Medical Education & Res Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego
WO2006029184A2 (fr) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes permettant de diagnostiquer et de surveiller les troubles associes a l'inflammation
EP2007899B1 (fr) * 2006-03-20 2017-06-07 Celldex Therapeutics, Inc. Anticorps dirigés contre la protéine 4 du type angiopoiétine et utilisations de ceux-ci
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US10202430B2 (en) * 2007-10-18 2019-02-12 Mayo Foundation For Medical Education And Research IgM-mediated receptor clustering and cell modulation
KR20110011676A (ko) * 2008-05-13 2011-02-08 제넨테크, 인크. 항-ＰｉｒＢ 항체
US9228023B2 (en) * 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
CA2815046C (fr) * 2010-10-19 2019-05-14 Mayo Foundation For Medical Education And Research Anticorps humains et utilisations diagnostiques et therapeutiques desdits anticorps pour le traitement de trouble neurologique
US11180543B2 (en) * 2014-11-07 2021-11-23 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof

Also Published As

Publication number Publication date
CN108285483A (zh) 2018-07-17
CA2870625A1 (fr) 2013-10-24
CN108285483B (zh) 2022-04-26
IN2014MN02274A (fr) 2015-08-07
NZ701278A (en) 2016-12-23
ES2655077T3 (es) 2018-02-16
JP2021000120A (ja) 2021-01-07
MX2014012651A (es) 2015-05-07
MX356347B (es) 2018-05-23
HK1207565A1 (en) 2016-02-05
IL266658A (en) 2019-07-31
EP2838562A4 (fr) 2015-09-30
WO2013158748A1 (fr) 2013-10-24
CN104379167A (zh) 2015-02-25
JP2019050832A (ja) 2019-04-04
EP2838562B1 (fr) 2017-08-30
JP2022107016A (ja) 2022-07-20
IL235118A0 (en) 2014-12-31
IL266658B (en) 2021-04-29
BR112014025898A2 (pt) 2017-11-07
EP3305323B1 (fr) 2021-02-17
JP2015520608A (ja) 2015-07-23
ES2870717T3 (es) 2021-10-27
JP6162219B2 (ja) 2017-07-12
EP3305323A1 (fr) 2018-04-11
IL235118B (en) 2019-06-30
US20150104460A1 (en) 2015-04-16
CA2870625C (fr) 2023-06-20
HK1258380A1 (zh) 2019-11-08
JP2017127329A (ja) 2017-07-27
EP2838562A1 (fr) 2015-02-25
CN104379167B (zh) 2018-02-13

Similar Documents

Publication Publication Date Title
IL266658A (en) Human antibodies and their specific linker sequences for use in stroke and ischemia or ischemic conditions
HK1209413A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof 5--2-
ZA201407927B (en) Anti-egfr antibodies and uses thereof
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
HK1202065A1 (en) Multispecific and multivalent binding proteins and uses thereof
EP2870170A4 (fr) Nouveaux peptides et leur utilisation
HK1205136A1 (en) Cdim binding proteins and uses thereof cdim
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
EP2832856A4 (fr) Anticorps anti-lamp5 et son utilisation
HK1208053A1 (en) Antibody against transporter and use thereof
EP2918600A4 (fr) Nouveau peptide et son utilisation
AP2015008228A0 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
GB201208372D0 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230415